132.14
price up icon0.38%   0.50
after-market 시간 외 거래: 132.14
loading
전일 마감가:
$131.64
열려 있는:
$133.12
하루 거래량:
1.26M
Relative Volume:
1.12
시가총액:
$13.08B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
44.79
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+0.09%
1개월 성능:
+3.41%
6개월 성능:
-11.15%
1년 성능:
-9.56%
1일 변동 폭
Value
$130.75
$133.12
1주일 범위
Value
$130.75
$135.00
52주 변동 폭
Value
$84.23
$157.98

뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile

Name
명칭
Neurocrine Biosciences Inc
Name
전화
(858) 617-7600
Name
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
직원
1,800
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
NBIX's Discussions on Twitter

NBIX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
132.14 13.03B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.12 68.04B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.48 46.30B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.88 44.25B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.54 18.73B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
304.50 13.82B 2.99B 1.21B 1.13B 25.06

뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-21 개시 Truist Buy
2025-07-10 개시 Goldman Buy
2025-04-15 업그레이드 Needham Hold → Buy
2025-04-14 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2025-02-11 개시 Deutsche Bank Hold
2024-10-10 재개 Raymond James Outperform
2024-08-29 업그레이드 Piper Sandler Neutral → Overweight
2024-04-24 업그레이드 Wells Fargo Equal Weight → Overweight
2023-12-13 재개 Citigroup Neutral
2023-12-12 개시 Deutsche Bank Buy
2023-10-24 재개 Cantor Fitzgerald Overweight
2023-08-21 재확인 Mizuho Neutral
2023-07-24 업그레이드 SVB Securities Market Perform → Outperform
2023-07-06 업그레이드 BMO Capital Markets Underperform → Market Perform
2023-05-04 업그레이드 Guggenheim Neutral → Buy
2023-03-30 업그레이드 Canaccord Genuity Hold → Buy
2023-03-03 업그레이드 Evercore ISI In-line → Outperform
2023-02-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-11-14 다운그레이드 Evercore ISI Outperform → In-line
2022-10-11 개시 UBS Buy
2022-09-26 개시 Wells Fargo Equal Weight
2022-06-06 재개 Jefferies Buy
2022-03-03 다운그레이드 Piper Sandler Overweight → Neutral
2022-02-25 업그레이드 Goldman Neutral → Buy
2022-01-18 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2021-11-19 개시 BMO Capital Markets Underperform
2021-11-17 업그레이드 JP Morgan Neutral → Overweight
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-08-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-05-18 재개 Goldman Neutral
2021-05-06 업그레이드 Barclays Equal Weight → Overweight
2021-02-02 개시 Raymond James Outperform
2020-09-30 개시 The Benchmark Company Hold
2020-08-04 다운그레이드 JP Morgan Overweight → Neutral
2020-06-29 다운그레이드 Goldman Buy → Neutral
2020-06-09 개시 Wedbush Outperform
2020-03-06 개시 Citigroup Buy
2020-02-27 개시 Barclays Equal Weight
2020-02-24 개시 William Blair Outperform
2020-02-06 개시 Mizuho Neutral
2020-02-05 재확인 H.C. Wainwright Buy
2019-12-13 다운그레이드 Credit Suisse Outperform → Neutral
2019-08-07 개시 RBC Capital Mkts Outperform
2019-07-16 개시 Oppenheimer Outperform
2019-06-05 개시 Guggenheim Neutral
2019-05-21 개시 Credit Suisse Outperform
2019-04-22 업그레이드 JP Morgan Neutral → Overweight
2019-04-12 개시 Evercore ISI Outperform
2019-02-06 재확인 BofA/Merrill Buy
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-12-13 개시 Goldman Buy
2018-11-21 개시 Canaccord Genuity Buy
모두보기

뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스

pulisher
12:04 PM

Why is Neurocrine Biosciences Inc. stock attracting strong analyst attentionSuperior stock selection - jammulinksnews.com

12:04 PM
pulisher
11:08 AM

Is Neurocrine Biosciences Inc. a growth stock or a value stockDiscover stocks with explosive upside potential - jammulinksnews.com

11:08 AM
pulisher
10:01 AM

Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence - Insider Monkey

10:01 AM
pulisher
08:36 AM

Is Neurocrine Biosciences Inc. stock overvalued or undervaluedGet daily expert analysis for smarter investing - jammulinksnews.com

08:36 AM
pulisher
Jul 26, 2025

Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Is Neurocrine Biosciences Inc. stock overhyped or has real potentialExponential wealth increase - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

Is Neurocrine Biosciences Inc. a good long term investmentRecord-breaking gains - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from Analysts at Truist Financial - MarketBeat

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Neurocrine Biosciences Inc. stockDynamic investment opportunities - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Neurocrine Biosciences Inc. stock priceRapidly growing investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Neurocrine Biosciences Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada

Jul 21, 2025
pulisher
Jul 18, 2025

Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st

Jul 18, 2025
pulisher
Jul 17, 2025

Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

Neurocrine reports positive results from Crenessity trial - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares registry data showing CAH treatment challenges - StreetInsider

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire

Jul 15, 2025
pulisher
Jul 15, 2025

New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress

Jul 14, 2025

뉴로크린 바이오사이언시스 (NBIX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Delaet Ingrid
Chief Regulatory Officer
Jul 10 '25
Sale
135.00
457
61,695
4,730
Onyia Jude
Chief Scientific Officer
Jul 09 '25
Option Exercise
84.74
59,819
5,069,062
78,108
Onyia Jude
Chief Scientific Officer
Jul 09 '25
Sale
130.46
59,819
7,803,688
18,289
$304.50
price down icon 0.62%
drug_manufacturers_specialty_generic RDY
$14.67
price down icon 0.27%
$9.41
price up icon 0.64%
$14.92
price up icon 1.57%
$16.54
price up icon 1.29%
자본화:     |  볼륨(24시간):